SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

SL BIO Ltd. completed its business combination with Horizon Space Acquisition II Corp., creating SL Science Holding Limited, which began trading on Nasdaq under ticker 'SLBT' on June 15, 2026. The transaction valued SL Bio at approximately $5.568 billion and raised $7.8 million in PIPE financing. The company plans to advance its proprietary Gamma delta T cell-based cellular therapies for solid tumors, including pancreatic and brain cancers, leveraging Nasdaq listing to access U.S. capital markets and pursue strategic growth.